A postulated model for photoimmunopathogenesis of chronic actinic dermatitis around adaptive immunity, including Th17 cells, Tregs, <scp>TRMs</scp>, cytotoxic T cells, and/or common‐γ chain receptor+ cells

Kim, Junghwan; Kim, Ho‐Jin; Yoo, Dong-Wha; Park, Kyung-Deok; Kwon, Huiyoung; Seo, Jung-Wan; Kim, Tae-Hoon; Yoon, Jung‐Ho; Seong, Seol Hwa; Jang, Min Soo; Kim, Kiho

doi:10.1111/phpp.12848

Cited by 5 publications

(3 citation statements)

References 23 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibition of this pathway using JAK inhibitors could be a promising treatment for a variety of skin disorders. 19 , 20 These inhibitors target various cell types, including CD8-positive T cells, and suppress the interferon-gamma and interleukin pathways by blocking the action of four key tyrosine kinases: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). Tofacitinib, a selective oral Janus Kinase inhibitor (JAK1 inhibitor), has proven effective in treating several T cell-mediated dermatoses such as psoriasis, atopic dermatitis, dermatomyositis, alopecia areata, and vitiligo, which do not respond to classical immunosuppressive therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have reported that CAD development is linked to dysregulated inflammation and oxidative stress. 5 , 20 Additionally, it’s also observed that CAD patients are more susceptible to infections following skin biopsy. 3 Photo allergy triggers the alteration of endogenous skin antigens, followed by inflammation mediated by CD8+ T cells, a process similar to the delayed-type hypersensitivity in allergic contact dermatitis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Successful Treatment of Chronic Actinic Dermatitis with Tofacitinib

Zhong,

Ali,

Yang

et al. 2024

CCID

View full text Add to dashboard Cite

We present the case of a 58-year-old male patient who presented with pruritic skin plaques and papules on the scalp, face, back, and back of the hands for over a year. The symptoms worsened upon exposure to sunlight and improved on cloudy days. Despite previous attempts at treatment with glucocorticoid ointment and antihistamine drugs, the patient experienced progressive aggravation of symptoms. Physical examination revealed hypertrophic and infiltrating nodules, with significant scratches and local exudation. Skin biopsy confirmed the diagnosis of sun-induced dermatosis. The patient was initiated on tofacitinib, an oral Janus Kinase inhibitor, along with a halometasone ointment, oral ebastine tablets, and strict sun protection. Over the course of four revisits spanning four months, the patient experienced a significant improvement in symptoms, with the rash almost disappearing and pruritus subsiding. The treatment was well tolerated and no adverse effects were observed. Follow-up for six months post-treatment showed no recurrence of symptoms. This case highlights the efficacy of tofacitinib in managing sun-induced pruritic plaques and suggests it as a potential therapeutic option in similar cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Chronic Actinic Dermatitis with Tofacitinib

Zhong,

Ali,

Yang

et al. 2024

CCID

View full text Add to dashboard Cite

show abstract

“… 18 It was reported that UV-induced CD3+, CD4+, and CD8+ cells increased in the more severe CSS-CAD subgroup and mediated their suppressive function by releasing immune regulatory cytokines such as IL-4 and IL-10. 19 Therefore, it has been speculated that immune imbalance plays an important role in the pathogenesis of CAD. A retrospective study of CAD patients over a 5-year period found that 16 (21.6%) of CAD patients with an early age of onset had an atopic history.…”

Section: Discussionmentioning

confidence: 99%

The Effectiveness and Safety of Dupilumab for the Treatment of Recalcitrant Chronic Actinic Dermatitis: A Case Series

Chen,

Yu,

et al. 2023

CCID

View full text Add to dashboard Cite

Background Although dupilumab is an effective treatment approach for chronic actinic dermatitis (CAD) in some cases, its effectiveness and safety in CAD have not been sufficiently assessed. Purpose Evaluation of the effectiveness and safety of dupilumab in patients with recalcitrant CAD was performed. Methods We retrospectively reviewed the medical records of CAD patients treated with dupilumab. Data regarding demographics were collected, and disease severity scores were assessed using the following: Clinical Severity Score of CAD (CSS-CAD), Atopic Dermatitis Control Tool (ADCT), Dermatology Life Quality Index (DLQI), and Numeric Rating Scale (NRS)-itch scores. Results After 12 weeks of treatment, there was a significant decrease in disease severity scores of 16 CAD patients. Only one patient achieved a good response and most of the patients (62.5%, 10/16) had no significant symptom improvement after 4 weeks of treatment. However, after 12 weeks of treatment, 43.75% (7/16) of the patients reached excellent response (>75% improvement of CSS-CAD), 31.25% (5/16) good response (50%–75% improvement of CSS-CAD), 6.25% (1/16) partial response (25%–50% improvement of CSS-CAD), and only 18.75% (3/16) no response (<25% improvement of CSS-CAD). One patient complained of injection site reaction at the first injection. Conclusion This study supports dupilumab as an effective and safe treatment option for patients with recalcitrant CAD. Patients may require at least 4 weeks of treatment before the partial response is noted.

show abstract

Reinforcing Photoprotection for Skin of Color: A Narrative Review

Tsai¹,

Chien²

2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Skin of color (SOC) is characterized by increased tendency for tanning and decreased likelihood of sunburns due to the attenuation of sunlight by epidermal melanin. Although this contributes to the decreased incidence of skin cancer among SOC populations, individuals with SOC remain susceptible to various health consequences associated with sun exposure, including non-melanoma skin cancer, photoaging, pigmentary disorders, and photodermatoses — many of which not only present differently, but also disproportionately affect SOC. Prior epidemiological studies have found lower prevalence of sun protection behaviors among individuals with SOC, particularly in sunscreen use, signifying an unmet area for improvement in the prevention of sun-induced dermatologic conditions in these populations. The objective of this narrative review was to summarize the biology and health consequences of sun exposure in SOC, as well as cognitive and behavioral factors that affect the practice of photoprotection behaviors in SOC populations. We also review prior interventions that have been used to enhance photoprotection knowledge and behaviors among individuals with SOC, either in racially and ethnically diverse communities or within specific SOC populations.

show abstract

A postulated model for photoimmunopathogenesis of chronic actinic dermatitis around adaptive immunity, including Th17 cells, Tregs, TRMs, cytotoxic T cells, and/or common‐γ chain receptor+ cells

Cited by 5 publications

References 23 publications

Successful Treatment of Chronic Actinic Dermatitis with Tofacitinib

Successful Treatment of Chronic Actinic Dermatitis with Tofacitinib

The Effectiveness and Safety of Dupilumab for the Treatment of Recalcitrant Chronic Actinic Dermatitis: A Case Series

Reinforcing Photoprotection for Skin of Color: A Narrative Review

Contact Info

Product

Resources

About